Cited by 280Cancer, Hypoxia, and MetabolismEpigenetics and DNA MethylationRNA modifications and cancer

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

l -2-Hydroxyglutarate: An Epigenetic Modifier and Putative Oncometabolite in Renal Cancer

Open access

Shim, Eun-Hee, Livi, Carolina B., Rakheja, Dinesh, Tan, Jubilee, Benson, Daniel, Parekh, Vishwas, Kho, Eun-Young, Ghosh, Arindam P., Kirkman, Richard, Velu, Sadanan, Dutta, Shilpa, Chenna, Balachandra, Rea, Shane L., Mishur, Robert J., Li, Qiuhua, Johnson-Pais, Teresa L., Guo, Lining, Bae, Sejong, Wei, Shi, Block, Karen, Sudarshan, Sunil·2014·Cancer Discovery

DOI 10.1158/2159-8290.cd-13-0696PMC PMC4286872

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Through unbiased metabolomics, we identified elevations of the metabolite 2-hydroxyglutarate (2HG) in renal cell carcinoma (RCC). 2HG can inhibit 2-oxoglutaratre (2-OG)–dependent dioxygenases that mediate epigenetic events, including DNA and histone demethylation. 2HG accumulation, specifically the d enantiomer, can result from gain-of-function mutations of isocitrate dehydrogenase (IDH1, IDH2) found in several different tumors. In contrast, kidney tumors demonstrate elevations of the l enantiomer of 2HG (l-2HG). High-2HG tumors demonstrate reduced DNA levels of 5-hydroxymethylcytosine (5hmC), consistent with 2HG-mediated inhibition of ten-eleven translocation (TET) enzymes, which convert 5-methylcytosine (5mC) to 5hmC. l-2HG elevation is mediated in part by reduced expression of l-2HG dehydrogenase (L2HGDH). L2HGDH reconstitution in RCC cells lowers l-2HG and promotes 5hmC accumulation. In addition, L2HGDH expression in RCC cells reduces histone methylation and suppresses in vitro tumor phenotypes. Our report identifies l-2HG as an epigenetic modifier and putative oncometabolite in kidney cancer. Significance: Here, we report elevations of the putative oncometabolite l-2HG in the most common subtype of kidney cancer and describe a novel mechanism for the regulation of DNA 5hmC levels. Our findings provide new insight into the metabolic basis for the epigenetic landscape of renal cancer. Cancer Discov; 4(11); 1290–8. ©2014 AACR. This article is highlighted in the In This Issue feature, p. 1243

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-13-0696

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
Sreekumar, A., Poisson, L., Rajendiran, T. M., Khan, A. P., Cao, Q., Yu, J., Laxman, B., Mehra, R., Lonigro, R. J., Li, Y., et al. (2009) · Nature · doi:10.1038/nature07762 · Cited by 2,269
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia
Metallo, C. M., Gameiro, P. A., Bell, E. L., Mattaini, K. R., Yang, J., Hiller, K., Jewell, C. M., Johnson, Z. R., Irvine, D. J., Guarente, L., et al. (2012) · Nature · doi:10.1038/nature10602 · Cited by 1,791
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer
The Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
Ko, M., Huang, Y., Jankowska, A. M., Pape, U. J., Tahiliani, M., Bandukwala, H. S., An, J., Lamperti, E. D., Koh, K. P., Ganetzky, R. D., et al. (2010) · Nature · doi:10.1038/nature09586 · Cited by 1,340
Integrated molecular analysis of clear-cell renal cell carcinoma
Sato, Y., Yoshizato, T., Shiraishi, Y., Maekawa, S., Okuno, Y., Kamura, T., Shimamura, T., Sato‐Otsubo, A., Nagae, G., Suzuki, H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2699 · Cited by 1,257

Show all 39 references

Sorted by citations

The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926
Fundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013
Mitochondrial TCA cycle metabolites control physiology and disease
Martínez-Reyes, I., & Chandel, N. S. (2020) · Nature Communications · doi:10.1038/s41467-019-13668-3 · Cited by 2,813
Understanding the Intersections between Metabolism and Cancer Biology
Heiden, M. G. V., & DeBerardinis, R. J. (2017) · Cell · doi:10.1016/j.cell.2016.12.039 · Cited by 2,369
Cancer metabolism: looking forward
Martínez‐Reyes, I., & Chandel, N. S. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00378-6 · Cited by 1,877
The hallmarks of cancer metabolism: still emerging
Pavlova, N. N., Zhu, J., & Thompson, C. B. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.01.007 · Cited by 1,418
Glutamine reliance in cell metabolism
Yoo, H. C., Yu, Y. C., Sung, Y., & Han, J. M. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00504-8 · Cited by 1,021
We need to talk about the Warburg effect
DeBerardinis, R. J., & Chandel, N. S. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0172-2 · Cited by 887
Metabolic reprogramming and epigenetic modifications on the path to cancer
Sun, L., Zhang, H., & Gao, P. (2021) · Protein & Cell · doi:10.1007/s13238-021-00846-7 · Cited by 818
Mitochondrial Metabolism as a Target for Cancer Therapy
Vasan, K., Werner, M., & Chandel, N. S. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.06.019 · Cited by 762
Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma
Ravi, V. M., Will, P., Kueckelhaus, J., Sun, N., Joseph, K., Salié, H., Vollmer, L., Kuliešiūtė, U., von Ehr, J., Benotmane, J. K., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.05.009 · Cited by 702
Mechanisms and Implications of Metabolic Heterogeneity in Cancer
Kim, J., & DeBerardinis, R. J. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.08.013 · Cited by 606
The hallmarks of cancer immune evasion
Galassi, C., Chan, T. A.-T., Vitale, I., & Galluzzi, L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.010 · Cited by 630
Metabolic reprogramming in clear cell renal cell carcinoma
Wettersten, H. I., Aboud, O. A., Lara, P. N., & Weiss, R. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.59 · Cited by 587
2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
Sulkowski, P. L., Corso, C. D., Robinson, N. D., Scanlon, S. E., Purshouse, K. R., Bai, H., Liu, Y., Sundaram, R. K., Hegan, D. C., Fons, N. R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal2463 · Cited by 575
The landscape of cancer cell line metabolism
Li, H., Ning, S., Ghandi, M., Kryukov, G. V., Gopal, S., Deik, A., Souza, A., Pierce, K. A., Keskula, P., Hernandez, D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0404-8 · Cited by 511
Hypoxia Induces Production of L-2-Hydroxyglutarate
Intlekofer, A. M., Dematteo, R. G., Venneti, S., Finley, L. W. S., Lu, C., Judkins, A. R., Rustenburg, A. S., Grinaway, P. B., Chodera, J. D., Cross, J. R., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.06.023 · Cited by 513
Oxygen availability and metabolic adaptations
Nakazawa, M. S., Keith, B., & Simon, M. C. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.84 · Cited by 446
Altered metabolite levels in cancer: implications for tumour biology and cancer therapy
Sullivan, L. B., Gui, D. Y., & Heiden, M. G. V. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.85 · Cited by 406
The AlkB family of Fe(II)/α-ketoglutarate-dependent dioxygenases: repairing nucleic acid alkylation damage and beyond
Fedeles, B. I., Singh, V., Delaney, J. C., Li, D., & Essigmann, J. M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.656462 · Cited by 416
Hypoxia-Mediated Increases in l -2-hydroxyglutarate Coordinate the Metabolic Response to Reductive Stress
Oldham, W. M., Clish, C. B., Yang, Y., & Loscalzo, J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.06.021 · Cited by 364
“…of regional hypoxia in tumor biology, this work also highlights the importance of enantiomeric characterization of 2HG elevations, particularly as L2HG has recently been identified in association with renal cell carcinoma tissues, many of which contained VHL mutations (Shim et al., 2014).”
The Significance of Mitochondrial Dysfunction in Cancer
Luo, Y., Ma, J., & Lu, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165598 · Cited by 380
LKB1 loss links serine metabolism to DNA methylation and tumorigenesis
Kottakis, F., Nicolay, B. N., Roumane, A., Karnik, R., Gu, H., Nagle, J. M., Boukhali, M., Hayward, M. C., Li, Y. Y., Chen, T., et al. (2016) · Nature · doi:10.1038/nature20132 · Cited by 348
What is cancer metabolism?
Finley, L. W. S. (2023) · Cell · doi:10.1016/j.cell.2023.01.038 · Cited by 343
The Metabolic Basis of Kidney Cancer
Linehan, W. M., Schmidt, L. S., Crooks, D. R., Wei, D., Srinivasan, R., Lang, M., & Ricketts, C. J. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1354 · Cited by 350
The mitochondrial respiratory chain is essential for haematopoietic stem cell function
Ansó, E., Weinberg, S. E., Diebold, L. P., Thompson, B. J., Malinge, S., Schumacker, P. T., Liu, X., Zhang, Y., Shao, Z., Steadman, M., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3529 · Cited by 327
Targeting Glioblastoma Stem Cells through Disruption of the Circadian Clock
Dong, Z., Zhang, G., Qu, M., Gimple, R. C., Wu, Q., Qiu, Z., Prager, B. C., Wang, X., Kim, L. J. Y., Morton, A. R., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0215 · Cited by 293
TET (Ten-eleven translocation) family proteins: structure, biological functions and applications
Zhang, X., Zhang, Y., Wang, C., & Wang, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01537-x · Cited by 297
L-2-Hydroxyglutarate production arises from noncanonical enzyme function at acidic pH
Intlekofer, A. M., Wang, B., Liu, H., Shah, H., Carmona-Fontaine, C., Rustenburg, A. S., Salah, S., Gunner, M. R., Chodera, J. D., Cross, J. R., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2307 · Cited by 268
Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches
Wong, C. C., Qian, Y., & Yu, J. Q. (2017) · Oncogene · doi:10.1038/onc.2016.485 · Cited by 266
Metabolic adaptation in hypoxia and cancer
Paredes, F., Williams, H. C., & Martín, A. S. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.020 · Cited by 276
Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma
Lucarelli, G. T., Loizzo, D., Franzin, R., Battaglia, S., Ferro, M., Cantiello, F., Castellano, G., Bettocchi, C., Ditonno, P., & Battaglia, M. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1607729 · Cited by 249
Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates
Ye, D., Guan, K.-L., & Xiong, Y. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2017.12.005 · Cited by 242
2-Oxoglutarate-dependent dioxygenases in cancer
Losman, J.-A., Koivunen, P., & Kaelin, W. G. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-00303-3 · Cited by 241
Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma
Lucarelli, G. T., Rutigliano, M., Sallustio, F., Ribatti, D., Giglio, A., Signorile, M. L., Grossi, V., Sanese, P., Napoli, A., Maiorano, E., et al. (2018) · Aging · doi:10.18632/aging.101685 · Cited by 231
Oncometabolites in renal cancer
Yong, C., Stewart, G. D., & Frezza, C. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0210-z · Cited by 216
Ascorbic Acid in Cancer Treatment: Let the Phoenix Fly
Shenoy, N. K., Creagan, E. T., Witzig, T. E., & Levine, M. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.014 · Cited by 208
Metabolic reprogramming in renal cancer: Events of a metabolic disease
Chakraborty, S., Balan, M., Sabarwal, A., Choueiri, T. K., & Pal, S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188559 · Cited by 214
Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities
Ge, T., Gu, X., Jia, R., Ge, S., Chai, P., Zhuang, A., & Fan, X. (2022) · 癌症：英文版 · doi:10.1002/cac2.12374 · Cited by 220
Moonlighting functions of metabolic enzymes and metabolites in cancer
Pan, C., Li, B., & Simon, M. C. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.08.031 · Cited by 198
Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets
di Meo, N. A., Lasorsa, F. M., Rutigliano, M., Loizzo, D., Ferro, M., Stella, A., Bizzoca, C., Vincenti, L., Pandolfo, S. D., Riccardo Autorino, B., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214360 · Cited by 182
Oncometabolites: Unconventional triggers of oncogenic signalling cascades
Sciacovelli, M., & Frezza, C. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.04.025 · Cited by 184
Loss of 5-hydroxymethylcytosine is linked to gene body hypermethylation in kidney cancer
Chen, K., Zhang, J., Guo, Z., Ma, Q., Xu, Z., Zhou, Y., Xu, Z., Li, Z., Liu, Y., Ye, X., et al. (2015) · Cell Research · doi:10.1038/cr.2015.150 · Cited by 177
A landscape of metabolic variation across tumor types
Reznik, E., Luna, A., Aksoy, B. A., Liu, E. M., La, K., Ostrovnaya, I., Creighton, C. J., Hakimi, A. A., & Sander, C. (2018) · Cell Systems · doi:10.1016/j.cels.2017.12.014 · Cited by 172
HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells
Lee, S.-H., Golinska, M., & Griffiths, J. R. (2021) · Cells · doi:10.3390/cells10092371 · Cited by 169
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Venneti, S., Kawakibi, A. R., Ji, S., Waszak, S. M., Sweha, S. R., Mota, M., Pun, M. J., Deogharkar, A., Chung, C., Tarapore, R. S., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0131 · Cited by 167
Metabolic remodelling during early mouse embryo development
Zhao, J., Yao, K., Yu, H., Zhang, L., Xu, Y., Chen, L., Sun, Z., Zhu, Y., Zhang, C., Qian, Y., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00464-x · Cited by 167
The Roles of 2-Hydroxyglutarate
Du, X., & Hu, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.651317 · Cited by 160
Dysregulation of the TET family of epigenetic regulators in lymphoid and myeloid malignancies
Lio, C. J., Yuita, H., & Rao, A. (2019) · Blood · doi:10.1182/blood.2019791475 · Cited by 152
Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling
Gagné, L. M., Boulay, K., Topisirović, I., Huot, M., & Mallette, F. A. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.06.002 · Cited by 143
The α-ketoglutarate dehydrogenase complex in cancer metabolic plasticity
Vatrinet, R., Leone, G., Luise, M. D., Girolimetti, G., Vidone, M., Gasparre, G., & Porcelli, A. M. (2017) · Cancer & Metabolism · doi:10.1186/s40170-017-0165-0 · Cited by 133
Nuclear metabolism and the regulation of the epigenome
Boon, R., da Silveira, G. G., & Mostoslavsky, R. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00285-4 · Cited by 129
Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight
Al‐Khallaf, H. (2017) · Cell & Bioscience · doi:10.1186/s13578-017-0165-3 · Cited by 133
Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets
Miranda‐Gonçalves, V., Lameirinhas, A., Henrique, R., & Jerónimo, C. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00427 · Cited by 125
Metabolic reprogramming and the role of mitochondria in polycystic kidney disease
Podrini, C., Cassina, L., & Boletta, A. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109495 · Cited by 124
Functional Assessment of Lipoyltransferase-1 Deficiency in Cells, Mice, and Humans
Ni, M., Solmonson, A., Pan, C., Yang, C., Li, D., Notzon, A., Cai, L., Guevara, G., Zacharias, L. G., Faubert, B., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.005 · Cited by 124
Self-citation
Interplay Among Metabolism, Epigenetic Modifications, and Gene Expression in Cancer
Huo, M., Zhang, J., Huang, W., & Wang, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.793428 · Cited by 117
Hallmarks of Pulmonary Hypertension: Mesenchymal and Inflammatory Cell Metabolic Reprogramming
D’Alessandro, A., Kasmi, K. C. E., Plecitá‐Hlavatá, L., Ježek, P., Li, M., Zhang, H., Gupte, S. A., & Stenmark, K. R. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7217 · Cited by 111
Glutamine Addiction in Kidney Cancer Suppresses Oxidative Stress and Can Be Exploited for Real-Time Imaging
Aboud, O. A., Habib, S. L., Trott, J. F., Stewart, B. J., Liang, S., Chaudhari, A. J., Sutcliffe-Goulden, J., & Weiss, R. H. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0930 · Cited by 110
Oncometabolite D-2-Hydroxyglurate Directly Induces Epithelial-Mesenchymal Transition and is Associated with Distant Metastasis in Colorectal Cancer
Colvin, H. S., Nishida, N., Konno, M., Haraguchi, N., Takahashi, H., Nishimura, J., Hata, T., Kawamoto, K., Asai, A., Tsunekuni, K., et al. (2016) · Scientific Reports · doi:10.1038/srep36289 · Cited by 111
Discovery and Validation of Clinical Biomarkers of Cancer: A Review Combining Metabolomics and Proteomics
Srivastava, A., & Creek, D. J. (2018) · PROTEOMICS · doi:10.1002/pmic.201700448 · Cited by 113
Ascorbic acid–induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma
Shenoy, N. K., Bhagat, T. D., Cheville, J. C., Lohse, C. M., Bhattacharyya, S., Tischer, A., Machha, V. R., Gordon-Mitchell, S., Choudhary, G. S., Wong, L.-F., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci98747 · Cited by 97
Self-citation
The multifaceted contribution of α-ketoglutarate to tumor progression: An opportunity to exploit?
Abla, H., Sollazzo, M., Gasparre, G., Iommarini, L., & Porcelli, A. M. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.031 · Cited by 99
TET2 in Normal and Malignant HematopoiesisPreprint
Bowman, R. L., & Levine, R. L. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026518 · Cited by 102
Oncometabolites: A New Paradigm for Oncology, Metabolism, and the Clinical Laboratory
Collins, R. R. J., Patel, K., Putnam, W. C., Kapur, P., & Rakheja, D. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.267666 · Cited by 94
Self-citation
Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer
Shelar, S. B., Shim, E., Brinkley, G. J., Kundu, A., Carobbio, F., Poston, T. L., Tan, J. C., Parekh, V., Benson, D. G., Crossman, D. K., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1727 · Cited by 89
Self-citation
Functional succinate dehydrogenase deficiency is a common adverse feature of clear cell renal cancer
Aggarwal, R. K., Luchtel, R. A., Machha, V. R., Tischer, A., Zou, Y., Pradhan, K., Ashai, N., Ramachandra, N., Albanese, J. M., Yang, J., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2106947118 · Cited by 94
ADHFE1 is a breast cancer oncogene and induces metabolic reprogramming
Mishra, P., Tang, W., Putluri, V., Dorsey, T. H., Jin, F., Wang, F., Zhu, D., Amable, L., Deng, T., Zhang, S., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93815 · Cited by 91
Advancing Cancer Treatment by Targeting Glutamine Metabolism—A Roadmap
Halama, A., & Suhre, K. (2022) · Cancers · doi:10.3390/cancers14030553 · Cited by 93
D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2
Lin, A., Abbas, S., Kim, S., Ortega, M. M., Bouamar, H., Escobedo, Y. A., Varadarajan, P., Qin, Y., Sudderth, J., Schulz, E., et al. (2015) · Nature Communications · doi:10.1038/ncomms8768 · Cited by 88
Self-citation
Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application
Li, M., Li, L., Zheng, J., Li, Z., Li, S., Wang, K., & Chen, X. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01745-7 · Cited by 89
Oncometabolites d - and l -2-Hydroxyglutarate Inhibit the AlkB Family DNA Repair Enzymes under Physiological Conditions
Chen, F., Bian, K., Tang, Q., Fedeles, B. I., Singh, V., Humulock, Z. T., Essigmann, J. M., & Li, D. (2017) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.7b00009 · Cited by 91
Novel drugs that target the metabolic reprogramming in renal cell cancer
van der Mijn, J. C., Panka, D. J., Geissler, A. K., Verheul, H. M. W., & Mier, J. W. (2016) · Cancer & Metabolism · doi:10.1186/s40170-016-0154-8 · Cited by 83
Drosophila larvae synthesize the putative oncometabolite L-2-hydroxyglutarate during normal developmental growth
Li, H., Chawla, G., Hurlburt, A. J., Sterrett, M. C., Zaslaver, O., Cox, J. E., Karty, J. A., Rosebrock, A. P., Caudy, A. A., & Tennessen, J. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614102114 · Cited by 76
Metabolic determinants of tumour initiation
Brunner, J. S., & Finley, L. W. S. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00773-5 · Cited by 78
Downregulation of HSP60 disrupts mitochondrial proteostasis to promote tumorigenesis and progression in clear cell renal cell carcinoma
Tang, H., Chen, Y., Liu, X., Wang, S., Lv, Y., Wu, D., Wang, Q., Luo, M., & Deng, H. (2016) · Oncotarget · doi:10.18632/oncotarget.9615 · Cited by 73
Metabolic Enzyme DLST Promotes Tumor Aggression and Reveals a Vulnerability to OXPHOS Inhibition in High-Risk Neuroblastoma
Anderson, N. M., Qin, X., Finan, J. M., Lam, A., Athoe, J., Missiaen, R., Skuli, N., Kennedy, A., Saini, A. S., Tao, T., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2153 · Cited by 70
TET Family of Dioxygenases: Crucial Roles and Underlying Mechanisms
Li, D., Guo, B., Wu, H., Tan, L., & Lu, Q. (2015) · Cytogenetic and Genome Research · doi:10.1159/000438853 · Cited by 74
Metabolomic study of human tissue and urine in clear cell renal carcinoma by LC-HRMS and PLS-DA
Nizioł, J., Bonifay, V., Ossoliński, K., Ossoliński, T., Ossolińska, A., Sunner, J. A., Beech, I. B., Arendowski, A., & Ruman, T. (2018) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-018-1059-x · Cited by 62
The Bidirectional Relationship Between Cancer Epigenetics and Metabolism
Izzo, L., Affronti, H. C., & Wellen, K. E. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070820-035832 · Cited by 64
The small members of the JMJD protein family: Enzymatic jewels or jinxes?
Oh, S., Shin, S., & Janknecht, R. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.04.002 · Cited by 60
Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health
Cheng, F., Liang, H., Butte, A. J., Eng, C., & Nussinov, R. (2018) · Pharmacological Reviews · doi:10.1124/pr.118.016253 · Cited by 58
Oncometabolites as biomarkers in thyroid cancer: a systematic review
Khatami, F., Payab, M., Sarvari, M., Gilany, K., Larijani, B. A., Arjmand, B., & Tavangar, S. M. (2019) · Cancer Management and Research · doi:10.2147/cmar.s188661 · Cited by 59
In vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma
Kaushik, A., Tarangelo, A., Boroughs, L. K., Ragavan, M., Zhang, Y., Wu, C., Li, X., Ahumada, K., Chiang, J., Tcheuyap, V. T., et al. (2022) · Science Advances · doi:10.1126/sciadv.abp8293 · Cited by 56
Connections between metabolism and epigenetics: mechanisms and novel anti-cancer strategy
Chen, C., Wang, Z., & Qin, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.935536 · Cited by 62
Signaling metabolite L-2-hydroxyglutarate activates the transcription factor HIF-1α in lipopolysaccharide-activated macrophages
Williams, N. C., Ryan, D. G., Costa, A. S. H., Mills, E. L., Jedrychowski, M. P., Cloonan, S. M., Frezza, C., & O'Neill, L. A. J. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101501 · Cited by 57
Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma
Jiang, H., Greathouse, R. L., Tiche, S. J., Zhao, M., He, B., Li, Y., Li, A. M., Forgo, B. L., Yip, M., Li, A., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1029 · Cited by 50
Comprehensive Metabolomic and Lipidomic Profiling of Human Kidney Tissue: A Platform Comparison
Leuthold, P., Schaeffeler, E., Winter, S., Büttner, F., Hofmann, U., Mürdter, T. E., Rausch, S., Sonntag, D., Wahrheit, J., Fend, F., et al. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00875 · Cited by 56
Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets
Karagiannakos, A., Adamaki, M., Tsintarakis, A., Vojtěšek, B., Fåhræus, R., Zoumpourlis, V. C., & Karakostis, K. (2022) · Cancers · doi:10.3390/cancers14030664 · Cited by 59
Metabolomics and the Multi-Omics View of Cancer
Wishart, D. S. (2022) · Metabolites · doi:10.3390/metabo12020154 · Cited by 57
Metabolic Rewiring and the Characterization of Oncometabolites
Beyoğlu, D., & Idle, J. R. (2021) · Cancers · doi:10.3390/cancers13122900 · Cited by 50
A cluster of long non-coding RNAs exhibit diagnostic and prognostic values in renal cell carcinoma
Cheng, G., Liu, D., Liang, H., Yang, H., Chen, K., & Zhang, X. (2019) · Aging · doi:10.18632/aging.102407 · Cited by 47
Enantioselective metabolomics by liquid chromatography-mass spectrometry
Calderón, C., & Lämmerhofer, M. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.114430 · Cited by 48
Global 5-Hydroxymethylcytosine Levels Are Profoundly Reduced in Multiple Genitourinary Malignancies
Munari, E., Chaux, A., Vaghasia, A. M., Taheri, D., Karram, S., Bezerra, S. M., González-Roibón, N., Nelson, W. G., Yegnasubramanian, S., Netto, G. J., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146302 · Cited by 46
Metabolomics of oncogene-specific metabolic reprogramming during breast cancer
Dai, C., Arceo, J., Arnold, J. M., Sreekumar, A., Dovic̀hi, N. J., Li, J., & Littlepage, L. E. (2018) · Cancer & Metabolism · doi:10.1186/s40170-018-0175-6 · Cited by 46
Integrative Epigenetic and Gene Expression Analysis of Renal Tumor Progression to Metastasis
Nam, H., Chandrashekar, D. S., Kundu, A., Shelar, S. B., Kho, E.-Y., Sonpavde, G., Naik, G., Ghatalia, P., Livi, C. B., Varambally, S., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0636 · Cited by 47
Self-citation
To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma
Bhavya, B., Reghuvaran, A. C., Madhusoodanan, U. K., Rajalakshmi, P., Krishnakumar, K., Easwer, H. V., Deepti, A. N., & Gopala, S. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-019-00730-3 · Cited by 46
Metabolite activation of tumorigenic signaling pathways in the tumor microenvironment
Low, V., Li, Z., & Blenis, J. (2022) · Science Signaling · doi:10.1126/scisignal.abj4220 · Cited by 44
PRDM16 suppresses HIF-targeted gene expression in kidney cancer
Kundu, A., Nam, H., Shelar, S. B., Chandrashekar, D. S., Brinkley, G. J., Karki, S., Mitchell, T., Livi, C. B., Buckhaults, P., Kirkman, R. L., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191005 · Cited by 43
Self-citation
The RNA N6-Methyladenosine Methyltransferase METTL3 Promotes the Progression of Kidney Cancer via N6-Methyladenosine-Dependent Translational Enhancement of ABCD1
Shi, Y. X., Dou, Y., Zhang, J., Qi, J., Xin, Z., Zhang, M., Xiao, Y. P., & Ci, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.737498 · Cited by 45

Authors: Shim, E.-H., Livi, C. B., Rakheja, D., Tan, J., Benson, D., Parekh, V., Kho, E.-Y., Ghosh, A. P., Kirkman, R., Velu, S., Dutta, S., Chenna, B., Rea, S. L., Mishur, R. J., Li, Q., Johnson-Pais, T. L., Guo, L., Bae, S., Wei, S., Block, K., & Sudarshan, S.
Affiliations: University of Alabama at Birmingham (US)
The University of Texas at San Antonio Health Science Center (US)
The University of Texas Southwestern Medical Center (US)
5Department of Chemistry, University of Alabama at Birmingham, Birmingham, Alabama.
7Department of Urology, University of Texas Health Sciences Center at San Antonio, San Antonio, Texas.
Metabolon (United States) (US)
Corresponding author: Sudarshan, Sunil
ORCID: Shim, Eun-Hee
Livi, Carolina B.
Rakheja, Dinesh
Parekh, Vishwas
Kirkman, Richard
Dutta, Shilpa
Chenna, Balachandra
Rea, Shane L.
Mishur, Robert J.
Li, Qiuhua
Guo, Lining
Bae, Sejong
Wei, Shi
Sudarshan, Sunil
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2014-11-01
Volume: 4
Issue: 11
Pages: 1290-1298
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-13-0696
PMC: PMC4286872
OpenAlex: W1984882020
Cited by: 280
References: 39
Citations by year: 2026: 12 · 2025: 11 · 2024: 27 · 2023: 17 · 2022: 42 · 2021: 35 · 2020: 23 · 2019: 28 · 2018: 23 · 2017: 25 · 2016: 21 · 2015: 15 · 2014: 1
FWCI: 6.60
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (UL1TR001120, KL2TR001118)
University of Texas Health Science Center at San Antonio
National Cancer Institute (P30CA054174, R01CA131272, R01 NCI CA131272, K08CA138774, P30CA013148)
National Center for Research Resources (UL1RR025767)
National Center for Advancing Translational Sciences
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
Keywords: L-2-hydroxyglutarate, renal cell carcinoma, oncometabolites, epigenetic regulators, 5-hydroxymethylcytosine, TET enzymes, IDH mutation, 2-oxoglutarate-dependent dioxygenase, histone methylation, DNA demethylation, histone demethylation, cancer metabolism
MeSH terms: Carcinoma, Renal Cell, Glutarates, Humans, Kidney Neoplasms, RNA, Messenger, Epigenesis, Genetic, Cell Line, Tumor, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

l -2-Hydroxyglutarate: An Epigenetic Modifier and Putative Oncometabolite in Renal Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks